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Post-traumatic stress disorder (PTSD) is a heterogeneous disorder that affects individuals exposed 
to trauma (e.g., combat, interpersonal violence, and natural disasters). It is characterized by 
hyperarousal, intrusive reminders of the trauma, avoidance of trauma-related cues, and negative 
cognition and mood. This heterogeneity indicates the presence of multiple neurobiological 
mechanisms underlying the development and maintenance of PTSD. Fear conditioning is a robust, 
translational experimental paradigm that can be employed to elucidate these mechanisms by 
allowing for the study of fear-related dimensions of PTSD (e.g., fear extinction, fear inhibition, and 
generalization of fear) across multiple units of analysis. Fear conditioning experiments have identified 
varying trajectories of the dimensions described, highlighting exciting new avenues of targeted, 
focused study. Additionally, fear conditioning studies provide a translational platform to develop 
novel interventions. The current review highlights the versatility of fear conditioning paradigms, 
the implications for pharmacological and non-pharmacological treatments, the robustness of 
these paradigms to span an array of neuroscientific measures (e.g., genetic studies), and finally 
the need to understand the boundary conditions under which these paradigms are effective. 
Further understanding these paradigms will ultimately allow for optimization of fear conditioning 
paradigms, a necessary step towards the advancement of PTSD treatment methods.
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IntroductIon
Post-traumatic stress disorder (PTSD) affects 8% of the general population and occurs at a much 
higher percentage in populations at risk of experiencing trauma; this includes military personnel and 
individuals living in low-socioeconomic urban environments (1, 2). The incidence of combat-related 
PTSD is expected to rise given the number of veterans returning from theaters of conflict in Iraq 
and Afghanistan. According to early reports, approximately 20% of Operation Iraqi Freedom and 
Operation Enduring Freedom (OEF and OIF, respectively) veterans presented with PTSD symptoms 
upon their return from combat (3). While these recent conflicts have generated new cases of PTSD, 
there remain a significant number of Vietnam veterans who have been experiencing persistent PTSD 
symptoms for as long as 40 years (4). Based on earlier work from our group, PTSD is equally as per-
vasive in low-socioeconomic urban environments including Atlanta, GA, USA (5, 6).
Post-traumatic stress disorder is the fifth most common psychiatric diagnosis and is not limited 
to the aforementioned groups (2, 7). Unfortunately, many of the traumatic events that precede the 
development of PTSD are not preventable, and we can expect new cases to develop as a result of 
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including fear inhibition (14), fear extinction (15), and stimulus 
generalization (16). In translational experimental paradigms, the 
general term extinction can refer to the learning process that occurs 
Key concePt 2 | Fear inhibition
Fear inhibition refers to the ability to inhibit a fear response in the presence 
of a safety signal and can be observed experimentally when a previously 
reinforced CS+ is presented in compound with a neutral, safe stimulus.
Key concePt 3 | Fear extinction
Fear extinction is a form of new learning that occurs when the previously 
reinforced CS+ is repeatedly presented in the absence of the aversive US. 
It is a translational tool, such that it is experimentally homologous to exposure 
therapy. Dysregulated fear extinction in patients with PTSD appears to 
manifest itself in at least three ways that may not be mutually exclusive.
during the non-reinforced presentation of a previously reinforced 
CS (termed extinction training) as well as the retention of extinc-
tion learning after a period of time has elapsed since extinction 
training [termed extinction recall; (17)].
Fear condItIonIng
Self-report measures of PTSD can often be subjective and unreli-
able. The high comorbidity of PTSD and depression highlights 
this problem; specifically, measures of PTSD and depression [as 
indexed by the Clinician Administered PTSD Scale (CAPS) and 
the Beck Depression Index (BDI), respectively) may reflect over-
lapping symptoms of negative affect (18, 19). Similarly, the symp-
tom dimensions used for a diagnosis may reflect complex sequelae 
resulting from an overlap in symptom presentation of multiple dis-
orders (20). Fear conditioning allows the use of quantitative objec-
tive measures to identify and differentiate components of PTSD, 
most notably those related to the dysregulation of fear processing.
Fear conditioning utilizes Pavlovian conditioning and involves 
the association of previously neutral stimuli with unpleasant or 
aversive events. Experimentally, a neutral stimulus (i.e., shape or 
sound) is spatially or temporally paired with an aversive uncon-
ditioned stimulus (US), typically a blast of air or a mild electric 
shock. Previously, the neutral stimulus comes to evoke the same 
response as the US, even in the absence of the US, and is termed the 
reinforced conditioned stimulus [CS+, Ref. (21)]. When conceptu-
alizing a traumatic experience according to the principles of fear 
conditioning, unconditioned fear responses (UCR) similar to those 
experienced at the time of trauma can subsequently be elicited by 
stimuli (termed conditioned stimuli or CSs) similar to those present 
at the time of the trauma (e.g., sights, sounds, smells, context).
Conditioned fear responses can be quantified experimentally in 
a variety of ways. Fear potentiation of the acoustic startle response 
is a commonly employed translational methodology for indexing 
learned fear. The acoustic startle response (“startle”) is character-
ized by an integrative reflex contraction of the skeletal musculature 
in response to a strong stimulus (e.g., loud noise) and is an ideal 
model for studying fear conditioning since the amygdala is directly 
inter-connected with the startle circuit (22–24). Fear-potentiated 
startle is defined as an increase in the magnitude of the startle 
response when it is elicited in the presence of a CS+ that has been 
repeatedly paired with an aversive US; this methodology inher-
ently includes a within-subject non-zero baseline measure of an 
widespread trauma across military and civilian populations. For 
example, returning veterans from the most recent combat theaters 
have been exposed to the unpredictable nature of urban warfare, 
which includes suicide bombings and improvised explosive devices 
(IEDs). In civilian populations from low-socioeconomic urban 
environments, there is risk of interpersonal violence and sexual 
assault. Further, victims of natural disasters, who can number in the 
thousands, can develop PTSD symptoms in the wake of unforeseen 
devastation to person and property (8). It is becoming increas-
ingly clear that one’s individual risk for developing PTSD following 
exposure to a traumatic event is influenced by both intrinsic (e.g., 
genomic) and extrinsic (e.g., social support network) factors.
Post-traumatic stress disorder is a heterogeneous disorder in 
which symptoms span four primary symptom clusters according 
to the recent Diagnostic and Statistical Manual of Mental Disorders, 
5th edition [DSM-5; (9)]. The DSM-5 PTSD symptoms clusters 
include: (1) re-experiencing, such as flashbacks and recurrent 
nightmares, (2) avoidance, which includes circumventing thoughts 
and feelings associated with the traumatic event, (3) negative cog-
nitions and mood, which encompasses detachment from others 
and a loss of interest in activities, and (4) hyperarousal, which can 
manifest itself as difficulty sleeping and feeling overly alert.
This heterogeneity implies the involvement of multiple neu-
robiological mechanisms, which underlie the development and 
maintenance of PTSD [for a comprehensive review, see (10)]. The 
classification of PTSD symptoms according to clusters provides 
some utility in the clinic; however, there is a movement in the 
field to adopt a new strategy focused on the study of neurobio-
logical mechanisms that “cut across” mental disorders and under-
lie multiple psychiatric disease states [Research Domain Criteria; 
RDoC; (11)]. A central tenet of the RDoC framework is “classifying 
psychopathology based on dimensions of observable behavioral 
and neurobiological measures.” RDoC focuses on several differ-
ent systems, including the Negative Valence System; the construct 
matrix for this system includes acute threat or fear, which can be 
measured across several units of analysis. The focus of this review is 
on fear-conditioning studies that are defined under this construct.
Fear conditioning paradigms provide a compelling translational 
platform for investigating the neural underpinnings of trauma- 
and stressor-related disorders, such as PTSD and anxiety disor-
Key concePt 1 | Fear conditioning
A paradigm where a neutral stimuli is paired with unpleasant/aversive event to 
conceptualize and objectively study a traumatic experience according to the 
principles of Pavlovian conditioning such that the unconditioned fear responses 
are similar to those experienced at the time of trauma that become elicited by 
stimuli similar to those present at the time of the trauma.
ders such as panic and specific phobia. Interestingly, the DSM-5 
no longer includes Criterion A2, or the presence of fear, helpless-
ness, or horror in response to a traumatic event, in the diagnostic 
criteria that must be endorsed for a clinical diagnosis of PTSD; 
however, dysregulation of fear conditioning-related phenotypes 
remains a central feature of this disorder (12). As described in a 
recent review by Weston (13), neural circuitry that includes the 
amygdaloid complex can be associated with at least 14 symptoms 
of PTSD and, as such, there remains compelling interest in develop-
ing and utilizing translational paradigms that index these circuits, 
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 individual’s acoustic startle response (25, 26). Fear-potentiated star-
tle is observed across species and is ideal for studying translational 
models of fear-related phenotypes (27).
In typical human fear-conditioning approaches, an acquisition 
phase is presented in which a previously neutral CS is paired with 
an aversive US such that the CS comes to predict the US and, as 
such, a fear response of interest is elicited (potentiation of startle as 
compared to baseline or increase in skin conductance in the pres-
ence of the CS+ as opposed to a non-reinforced CS−). In addition, 
many paradigms will include a real-time measure of US-expectancy 
such that participants report their prediction of the presence or 
absence of a CS on a trial-by-trial basis. This allows investigators 
to determine whether participants can accurately discriminate 
between danger cues (CS+) and safety cues (CS). These measures 
further allow investigators to discern a psychophysiological, but 
not a cognitive, response consistent with a dysregulated system. 
For example, PTSD patients have shown increased fear responses 
to cues that they subjectively report as safe (28).
Following an Acquisition phase, translational studies of condi-
tioned fear will often employ one of three procedures for measur-
ing the expression and/or inhibition of the newly acquired fear: 
(1) fear extinction, (2) fear inhibition, or (3) generalization of 
fear. Alterations in fear extinction, fear inhibition, and stimulus 
Key concePt 4 | Fear-potentiated startle
Conditioned fear responses can be quantified experimentally in a variety of 
ways and fear potentiation of the acoustic startle response is a commonly 
employed translational methodology for quantitatively indexing learned fear 
across mammalian species. It refers to the relative increase from baseline 
startle in the presence of a fearful stimulus.
Key concePt 5 | Generalization of fear
Generalization of fear or stimulus generalization refers to the ability to discern 
fearful and safety cues. Generalization is a measure of the degree to which 
a conditioned fear response is expressed in the presence of generalization 
stimuli that vary incrementally from an initially presented CS+.
FiGure 1 | Promising targets for the translational study of trauma-, 
stressor-, and anxiety-related fear behaviors: trauma-, stressor-, and 
anxiety-related disorders have been shown to have a significant degree of 
heritability and more recently, it has become increasingly clear that 
genetic contributions include complex gene × environment interactions. 
Understanding these complex relationships may allow for early interventions 
to enhance resiliency in certain individuals with a high risk of trauma. 
Fear-conditioning paradigms afford the study of intermediate phenotypes, 
which may enhance our ability to elucidate these complex interactions [see 
Ref. (36)]. The dysregulated fear learning commonly observed in anxious and 
traumatized populations can be modeled by fear-conditioning paradigms, which 
can provide a translational framework. Translational studies have shown that 
fearful memories are initially labile and are consolidated to a more permanent 
state, hours to days, after the initial event. Modeling the process of 
consolidation and reconsolidation with fear-conditioning techniques provides an 
avenue to study potential pharmacological and non-pharmacological 
interventions [e.g., Ref. (33, 37)]. Clinically, individuals with PTSD have been 
show to have alterations in stimulus generalization (16), fear inhibition (29), 
discrimination, and fear extinction (38). In addition to complementary 
psychophysiological methods (e.g., skin conductance, reaction time), 
fear-potentiated startle methods have proven to be quite useful for the study 
and/or manipulation of these targets to better understand and treat stressor-, 
trauma-, and anxiety-related disorders. Figure adapted from Jovanovic and 
Ressler (39).
generalization have all been reported, using fear-potentiated startle 
methods, in populations with trauma- and stressor-related as well 
as anxiety disorders [see Figure 1; (16, 29–31)]. Fear extinction 
is a form of new learning that occurs when the previously rein-
forced CS+ is repeatedly presented in the absence of the aversive 
US [e.g., Ref. (17)]. Despite some recent reports to the contrary 
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[e.g., Ref. (32, 33)], the predominant understanding is that the 
original fear memory (CS–US association) is not erased, but com-
petes with new extinction learning, and can be accessed through 
the processes of spontaneous recovery (following the passage of 
time), renewal (shift in context), or reinstatement (the unsignaled 
presentation of the aversive US). Fear inhibition has traditionally 
been observed when a previously reinforced CS+ (termed cue A) 
is presented in compound with a neutral stimulus [termed the AB 
compound; (34)]. More recent studies of fear inhibition have used 
compound stimuli in which one compound is reinforced (termed 
AX+), another is non-reinforced (termed BX−) during acquisition. 
Fear inhibition is then measured as the transfer of the inhibitory 
(safe) properties of stimulus B onto stimulus A [via presentation 
of an AB compound; (29, 35)]. Generalization of fear (or stimu-
lus generalization) has been more widely studied recently and is 
a measure of the degree to which a conditioned fear response is 
expressed in the presence of generalization stimuli (GSs) that vary 
incrementally from an initially presented CS+ [e.g., concentric rings 
of increasing or decreasing diameter from the original CS+; (27); 
or morphed faces of which one is the CS+; (31)].
Fear extinction, as a translational tool, is an important area of 
study due to its relevance to the limbic neural circuitry believed 
to underlie fear psychopathology and also due to its role as an 
experimental homolog to exposure therapy, which is currently 
recognized as the most effective treatment for fear and anxiety. 
Dysregulated fear extinction in patients with PTSD symptoms 
appears to manifest itself in at least three ways that may not be 
mutually exclusive: over-expression of acquired fear, impaired 
within-session extinction learning (decrease in fear observed 
during the experimental session), and impaired between-session 
extinction retention (decrease in fear from one session to the next, 
which reflects memory consolidation processes). With regard to 
over-expression of acquired fear, previous work from our lab (15) 
suggests that the early phase of within-session extinction learn-
ing involves persistent excitation, as it is predicted by the level of 
fear expression to the CS+ (i.e., the danger signal) at the end of 
acquisition. For example, our group showed heightened levels of 
fear during early extinction in a previously traumatized popula-
tion with PTSD consisting of primarily African-American women 
living in a low-socioeconomic urban environment; we termed this 
pattern of extinction learning as being indicative of “fear load,” 
or the over-expression of fear during early extinction. High levels 
of conditioned fear remaining during late extinction are related 
to impaired inhibition, as it is best predicted by responses to the 
CS− (i.e., safety signal) at the end of acquisition (15). This is based 
on the notion that extinction learning is a form of fear inhibition. 
As an example, we previously showed that a predominately male 
population of combat veterans with PTSD did not show “fear load,” 
but rather impaired within-session extinction learning character-
ized by a “persistence of fear” (40). Lastly, work by Milad and oth-
ers (41, 42) demonstrated that individuals with PTSD showed a 
reduced ability to recall extinction learning when tested 24 h after 
within-session extinction learning had occurred. The presence of 
divergent extinction trajectories as described above represents an 
exciting new avenue of study and has recently been introduced in 
the rodent literature (43), which may be analogous to heterogene-
ous responses to trauma in PTSD (44).
unIts oF analysIs
While PTSD symptom clusters provide a useful set of diagnostic 
criteria and could be used to discern the most effective treatment 
[for a comprehensive review, see Ref. (10)], they represent broad 
categories of behavior and do not easily reflect common underlying 
mechanisms. Using the RDoC approach, fear-conditioning stud-
ies can identify intermediate phenotypes, which represent specific 
components of a disorder and allow for a more direct examination 
of brain–behavior relationships. We define intermediate pheno-
types as observable units that are (1) related to the underlying 
neurobiology of a disorder, (2) related to clinical symptoms of the 
disorder, and (3) are ideally possible to model in animal studies 
affording a translational approach. Unlike an endophenotype, an 
intermediate phenotype does not necessarily require heritability. An 
intermediate phenotype can be assessed with different units of anal-
ysis, including molecular, neural circuitry, physiology, behavior, and 
self-reports such as those listed in the RDoC matrix (http://www.
nimh.nih.gov/research-priorities/rdoc/nimh-research-domain-
criteria-rdoc.shtml). For the purpose of this review, we focused 
on physiological units of analysis, including fear-potentiated star-
tle and skin conductance response as fear conditioning-related 
intermediate phenotypes.
Key concePt 6 | Fear conditioning-related intermediate phenotypes
Observable units that are (1) related to the underlying neurobiology of a 
disorder, (2) related to clinical symptoms of the disorder, and (3) are ideally 
possible to model in animal studies affording a translational approach.
Numerous translational studies have employed fear- conditioning 
paradigms to better identify more basic dimensions and phenotypes 
associated within these diagnostic criteria. For example, previous 
work has shown that subjects with high hyperarousal symptoms 
show the greatest difficulty inhibiting a fear response to safety 
cues (45). In addition, during extinction learning, increased fear-
potentiated startle was associated with re-experiencing symptoms 
of PTSD (15). The same study showed a more robust fear response 
to both the CS+ (danger cue) and the CS− (safety cue) during 
acquisition that was associated with higher re-experiencing and 
hyperarousal symptoms.
Research has indicated that fear conditioning and cognitive 
biases share a common underlying neural mechanism, amygdala-
prefrontal circuitry (46). One aspect of cognitive bias, attention 
bias, or the facilitated orientation toward, or avoidance of, specific 
cues, has been shown to be a useful index of anxiety-related disor-
ders (46). This proposed connection between attention bias and fear 
conditioning has been explicitly examined. Fani et al. (47) showed 
that attention bias toward threat is associated with over-expression 
of fear during early extinction, referred to as “fear load.” This study 
provides further evidence of the utility of intermediate phenotypes 
to enhance our understanding of underlying neural circuitry and 
corresponding behavioral responses.
Further, PTSD has long been associated with intrinsic [e.g., age 
and gender (48, 49)], environmental (e.g., exposure to trauma, rear-
ing environment, degree of social support), and genetic factors (50–
52). The dysregulated fear learning observed in subjects with PTSD 
likely reflects the complexity of these interactions. Specifically, sev-
eral candidate gene studies have identified genetic differences and 
specific gene pathways involved in PTSD [for a review, see (53)]. 
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When conducting both candidate gene studies and genome-wide 
association studies (GWAS), it is common for the resulting genetic 
findings to associate with many disorders or only to distinct phe-
notypes of broader disorders, a central concern outlined in RDoC. 
It is useful to instead study intermediate phenotypes or specific 
components of disorders. For example, we recently showed that 
increased “fear load,” as measured by fear-potentiated startle was 
related to the catechol-O-methyl-transferase (COMT) Val66Met 
polymorphism and a diagnosis of PTSD (36). More recently, GWAS 
data, which is obtained when expression levels of the whole genome 
are analyzed in the context of PTSD, have been used to identify novel 
gene pathways involved in the mechanisms underlying complex 
disorders such as PTSD [see Ref. (54) for a review]. The use of these 
intermediate phenotypes not only enhances the ability to identify 
complex gene interactions but also allows for these gene pathways 
to be more readily studied. Fear conditioning provides a potential 
framework for studying these phenotypes [see Ref. (55, 56)].
VersatIlIty
Fear-potentiated startle can be used in several mammalian species 
(57); however, in animal models the CSs are typically auditory, 
whereas visual CSs are used in human studies. In order to bridge this 
gap, Norrholm and colleagues examined the use of auditory and 
visual CSs in fear conditioning of healthy participants (58). Briefly, 
healthy participants acquired fear to auditory stimuli comparable 
to the participants who were fear conditioned with visual stimuli. 
Both groups also discriminated between the CS+ and CS−; however, 
the auditory group exhibited discrimination on blocks 1, 2, and 3 of 
fear acquisition, while the visual CS+ group exhibited discrimina-
tion on blocks 2 and 3 of fear acquisition. Ten minutes after this 
initial assessment, these groups were shown to also extinguish fear; 
however, the auditory group displayed a steeper slope of extinction, 
due in part to an initial increase in fear during extinction, than 
the visual group. Twenty-four hours later an extinction test was 
performed. This test showed that spontaneous recovery occurred in 
both groups and US-expectancy ratings increased in both groups 
regardless of modality as well (58). The advantage of this versatil-
ity is that it can be used in patients with visual impairment with 
equivalent results and also lends itself to the use of “cross-over” 
longitudinal studies in which practice effects can be minimized.
treatment
Not surprisingly, treatment approaches aimed at reducing the 
fear-related symptoms of PTSD (e.g., re-experiencing and intru-
sive memories) have focused on the disruption of fear memory 
consolidation/reconsolidation, facilitation of extinction learning, 
and the prevention of the return of fear. Several recent translational 
studies have explored both pharmacological as well as non-phar-
macological means of enhancing extinction of fear and preventing 
its re-emergence. Memory consolidation refers to the process of 
transforming a memory (e.g., fear memory) from a labile state 
immediately after acquisition to a more permanent state that occurs 
after some time [believed to be 6 h or more post-acquisition; e.g., 
Ref. (59)]. Clinically speaking, memory consolidation first occurs 
at the time at which the traumatic event occurs. Many cellular pro-
cesses have been described as underlying the neural mechanisms of 
consolidation, including the activation of β-adrenergic receptors 
in amygdala; however, administration of the β-adrenergic receptor 
antagonist, propranolol, while initially promising, has not shown 
any significant effects regarding memory consolidation in large 
scale studies (60, 61). Morphine has also been studied as a possible 
intervention of fear memory consolidation; however, it is not clear 
whether morphine’s analgesic properties act to reduce the potency 
of the CS+ or are acting through a separate mechanism (61, 62).
With regard to the facilitation of extinction learning, a poten-
tial avenue was revealed by Davis and colleagues who reported 
that learning to extinguish conditioned fear was dependent on 
N-methyl-d-aspartate (NMDA) glutamate receptors in limbic 
regions including the amygdala (63). A decade later, Walker et al. 
(64) found that d-cycloserine (DCS), an NMDA receptor partial 
agonist, facilitated extinction learning in rats; a finding that was 
later replicated by several other groups employing multiple types 
of fear learning paradigms in rodents [e.g., Ref. (65)] but not rep-
licated using skin conductance and expectancy ratings in humans 
(66). Shortly thereafter, several groups reported that DCS admin-
istration before or after exposure therapy, a form of treatment 
based on the principles of fear extinction learning, was effective 
in alleviating the symptoms of acrophobia (67), panic disorder 
(68), social anxiety disorder (69, 70), and obsessive–compulsive 
disorder (71–73).
At present, the effectiveness of DCS in facilitating exposure 
therapy (i.e., extinction learning) for PTSD is unclear due to mixed 
reports in the extant literature. DCS has been shown to be effective 
under specific clinical conditions. For example, de Kleine and col-
leagues reported increased improvement in the symptom ratings of 
patients who were administered DCS and initially reported more 
severe symptom severity (74). Initial reports by Litz et al. (75) sug-
gested that DCS + exposure therapy was not as effective as placebo 
+ exposure in a population of combat veterans with PTSD (75) 
However, more recent reports from the latter group suggest that 
the effectiveness of DCS as an adjunct therapy may be related to 
the degree of fear reduction observed during individual exposure 
therapy sessions (76, 77) Additionally, a recent study used DCS in 
addition to virtual reality exposure therapy in patients suffering 
PTSD as a result of the 9/11 attacks and found significant clinical 
advantages of DCS compared to placebo (78). Specifically, when 
DCS was administered prior to virtual reality exposure therapy 
subjects showed earlier, enhanced symptom reduction and greater 
PTSD remission rates (78). Finally, trauma imagery-potentiated 
startle responses in recently returned combat veterans from Iraq 
and Afghanistan were significantly reduced in individuals who pre-
viously received DCS before each of five sessions of virtual reality 
exposure therapy for PTSD (38).
In addition to agents that act on glutamatergic systems, other 
pharmacological approaches have been examined as possible thera-
pies for fear- and anxiety-related disorders because of their poten-
tial to facilitate extinction learning and/or prevent the return of fear. 
Key concePt 7 | Memory consolidation
Memory consolidation is the process of transforming a memory (e.g., fear 
memory) from a labile state immediately after acquisition to a more permanent 
state that occurs after sometime. This process has been the target for non-
pharmacological attempts to facilitate fear extinction and prevent the return 
of conditioned fear in humans.
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skin  conductance measures, showed that retrieval + extinction 
(with 10 min but not 6 h between sessions) attenuated sponta-
neous recovery and reinstatement of fear in human subjects, an 
effect that was evident a year after the original acquisition of fear.
Similar to the aforementioned studies using immediate versus 
delayed extinction, attempts to replicate the retrieval + extinction 
effects reported by the Monfils et al. (33) and Schiller et al. (59) 
groups have yielded mixed results in human studies. It has become 
apparent that there are specific boundary conditions under which 
Pre-clinical rodent studies have shown that monoaminergic spe-
cific antidepressants such as venlafaxine (serotonin–norepineph-
rine reuptake inhibitor; SNRI) and fluoxetine (serotonin specific 
reuptake inhibitor; SSRI) can facilitate between-session extinction 
(79, 80) and prevent reinstatement of conditioned fear (80, 81). 
Although the use of antidepressants has not been widely studied in 
extinction of fear-potentiated startle studies, there is some evidence 
from skin conductance-based investigations suggesting a facilita-
tory role of these drugs in fear extinction learning (82).
The endocannabinoid system has also been implicated in 
conditioned fear extinction and represents an additional area of 
exploration for facilitating extinction and prevention of fear return. 
Chhatwal et al. (83) showed that enhanced cannabinoid recep-
tor CB1 activation (via administration of AM404, an agent that 
prevents endocannabinoid degradation and reuptake) facilitated 
within-session and between-session extinction of fear-potentiated 
startle as well as reinstatement in mice (83). This work was fur-
thered by Gunduz-Cinar et al. (84, 85) who showed that inhibition 
of fatty acid amide hydrolase (FAAH), the enzyme that catabolizes 
the endogenous cannabinoid anandamide, enhances extinction 
learning in rodents and could represent a risk variant for stressor-
related psychiatric disorders (84, 85).
New avenues for exploration continue to emerge and repre-
sent expanding opportunities to apply the fear conditioning and 
extinction procedures described herein. For example, Acheson and 
colleagues showed that the extinction of fear-potentiated startle in 
healthy humans could be enhanced with the intranasal adminis-
tration of oxytocin (86). In addition, recent evidence from mouse 
studies implicates the renin–angiotensin system in the regulation 
of fear and anxiety responses as angiotensin receptor AT1 antago-
nism with the anti-hypertension drug losartan has been shown to 
enhance fear extinction learning [extinction recall; (87)].
Non-pharmacological attempts to facilitate fear extinction and 
prevent the return of conditioned fear in humans have focused on 
the disruption of the original fear memory trace (CS–US associa-
tion) by interfering with consolidation or reconsolidation follow-
ing retrieval of a previously stored fear memory. One approach for 
disrupting consolidation of fear memories (CS–US association) 
that has been explored is immediate versus delayed extinction 
training. Myers et al. (32) showed that extinction training initi-
ated immediately after (10 min) fear acquisition prevented the 
return of learned fear via reinstatement, renewal, or spontaneous 
recovery. It was believed that extinction training, while the CS–US 
association was still labile, provided updated information regarding 
the association between the CS and US before the original associa-
tion had been consolidated. This finding was not well replicated 
in rodents [see Ref. (88, 89)] and was only weakly observed in 
humans [see Ref. (90)].
More recently, Monfils et al. (33) developed a paradigm termed 
retrieval + extinction in which a single CS+ trial is presented with-
out the US to open a reconsolidation window in which the origi-
nal fear memory is returned to a labile state. Extinction training 
is then administered within this reconsolidation window (e.g., 
1 h) in an effort to disrupt reconsolidation of the original fear 
memory. Monfils and colleagues showed that retrieval + extinc-
tion effectively attenuated the return of fear through renewal or 
reinstatement (33). Following this work, Schiller et al. (59), using 
Key concePt 8 | Boundary conditions
Boundary conditions are the conditions under which fear conditioning 
paradigms (e.g., retrieval + extinction) are effective. For example, these 
conditions include, but are not limited to, the type of psychophysiological 
measure employed (e.g., skin conductance), the schedule of reinforcement 
used during acquisition, and the strength of the fear memory following 
acquisition.
retrieval + extinction is effective. These conditions include, but are 
not limited to, the type of psychophysiological measure employed, 
the schedule of reinforcement used during acquisition, the fear-
relevancy of the conditioned stimuli presented, the strength of the 
fear memory following acquisition, and the presence or absence 
of on-line measures of expectancy or fear ratings [see Ref. (37, 
91–93)].
conclusIon
The utility of fear conditioning-related intermediate phenotypes 
can be observed across multiple units of analysis. Understanding 
these phenotypes (i.e., fear inhibition, high fear load, fear gener-
alization, etc.) and the divergent manifestations of these responses 
in the context of a broader etiology (i.e., genetic, behavioral, symp-
tomatic, and clinical studies) may lead to more effective treatment 
and preventative strategies for PTSD and other trauma-, stressor-, 
and anxiety-related disorders.
While the present review summarized the current progress of 
interfacing fear conditioning-related intermediate phenotypes and 
genetic (54), behavioral (47), symptomatic (15, 45), and clinical 
studies (78), further characterization of these intermediate phe-
notypes will enhance the utility of fear-conditioning studies. 
For example, PTSD is known to affect women more commonly 
than men (1, 94), and fear-conditioning paradigms are useful for 
characterizing the sex differences underlying different neuronal, 
endocrine, and behavioral responses to trauma and other stressors. 
For example, a polymorphism in the pituitary adenylate cyclase-
activating polypeptide receptor gene (ADCYAP1R1) is associated 
with decreased fear discrimination in females but not males (95). 
These findings illustrate the association between genetic risk, brain–
behavior interactions, and intermediate phenotypes.
Ultimately, potential breakthroughs will increase the utility of 
fear-conditioning studies as a translational platform for studying 
the intermediate phenotypes underlying dysregulated fear learning, 
a central tenant of trauma-, stressor-, and anxiety-related disor-
ders. This is especially useful due to the high comorbidity of PTSD 
and other disorders including depression and substance abuse. By 
identifying these intermediate phenotypes, we can create specific 
testable measures, which can then be used to examine the effective-
ness of treatment interventions.
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